Coronavirus Disease-2019 Vaccines and the Vaccination Challenges in India: A Review
DOI:
https://doi.org/10.17140/IMOJ-5-117Keywords:
SARS-CoV-2, COVID-19, Vaccine, COVID-19 treatmentAbstract
The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) designated as novel coronavirus is a cause of highly infectious disease referred to as coronavirus disease-2019 (COVID-19). The global pandemic that affected millions of people worldwide has claimed many lives and brought about catastrophe in low-income countries. The high mortality and rapid spread of the infection have brought about an urgent need for a safe and effective vaccine to control the pandemic. In this perspective, it becomes essential to understand the structure, mode of transmission, and virulence of SARS-Cov-2. In this article, an emphasis is made on understanding the infection pathogenesis and the host defense mechanisms against the infection to break the chain of transmission. Furthermore, we have tried to summarize the development and characteristics of different types of COVID-19 vaccines. In addition to this, we have highlighted the challenges of the public health system in the procurement and delivery of the vaccine to the community and especially to the most vulnerable society. It becomes the main priority to find support financially and make the public health system ready to imbibe the importance of vaccination through meticulous strategies so that vaccine reaches out to the community.
References
Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020; 5(5): 425-427. doi: 10.1016/S2468-1253(20)30076-5
World Health Organization (WHO). India: WHO Coronavirus Disease (COVID-19) Dashboard. Web site. https://covid19.who. int/region/searo/country/in. Accessed September 22, 2021.
Lee P-I, Hsueh P-R. Emerging threats from zoonotic corona-viruses-from SARS and MERS to 2019-nCoV. Journal of Micro-biology, Immunology and Infection. 2020; 53: 365-367. doi: 10.1016/j. jmii.2020.02.001
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wu-han, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020; 382: 1199-1207. doi: 10.1056/NEJMoa2001316
Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Vee-sler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 183(6): 281-292.e6. doi: 10.1016/j. cell.2020.02.058
Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Micro-biol. 2013; 11(12): 836-848. doi: 10.1038/nrmicro3143
Roper RL, Rehm KE. SARS vaccines: Where are we? Expert Rev Vaccines. 2009; 8(7): 887-898. doi: 10.1586/erv.09.43
Rihan FA, Al-Salti NS, Anwar MNY. Dynamics of coronavirus infection in human. AIP Conference Proceedings. 1982; 020009 (2018): doi: 10.1063/1.5045415
Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavi-rus to protective immunity. Proc Natl Acad Sci U S A. 2004; 101(26): 9804-9809. doi: 10.1073/pnas.0403492101
World Health Organization (WHO). WHO Coronavirus Dis-ease (COVID-19) Dashboard. Available from: https://covid19. who.int/. Accessed June 28, 2020.
Callaway E. The race for coronavirus vaccines: A graphical guide. Nature. 2020; 580(7805): 576-577. doi: 10.1038/d41586- 020-01221-y
WHO Ebola Response Team, Agua-Agum J, Allegranzi B, et al. After ebola in West Africa — unpredictable risks, preventable epidemics. N Engl J Med. 2016; 375(6): 587-596. doi: 10.1056/ NEJMsr1513109
Pfizer. Pfizer and BioNTech Submit COVID-19 Vaccine Sta-bility Data at Standard Freezer Temperature to the U.S. FDA. Web site. Available from: https://www.pfizer.com/news/press-release/ press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data. Accessed March 25, 2021.
Lurie N, Saville M, Hatchett R, Halton J. Developing COV-ID-19 vaccines at pandemic speed. N Engl J Med. 2020; 382(21): 1969-1973. doi: 10.1056/NEJMp2005630
Centers for Disease Control and Prevention (CDC). Johnson & Johnson’s Janssen COVID-19 Vaccine Information. Web site. https://www.cdc.gov/vaccines/covid-19/info-by-product/jans-sen/index.html. Accessed March 25, 2021.
Sharun K, Dhama K. India’s role in COVID-19 vaccine diplo-macy. J Travel Med. 2021; 28: (taab064). doi: 10.1093/jtm/taab064
Choudhary OP, Choudhary P, Singh I. India’s COVID-19 vac-cination drive: Key challenges and resolutions. Lancet Infect Dis. 2021; 21(11): 1483-1484. doi: 10.1016/S1473-3099(21)00567-3
Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strat-egy for COVID-19 vaccination in India: The country with the sec-ond highest population and number of cases. npj Vaccines. 2021; 6(1): 1-7. doi: 10.1038/s41541-021-00327-2
Ministry of Health and Family Welfare. Information regard-ing COVID-19 vaccine. Web site. https://www.mohfw.gov.in/co-vid_vaccination/vaccination/index.html. Accessed September 23, 2021.
Chakraborty C, Ranjan Sharma A, Bhattacharya M, Lee S-S, Agoramoorthy G. COVID-19 vaccine: Challenges in developing countries and India’s initiatives. Infez Med. 2021; 29(1): 165-166.
Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee S-S, Chakraborty C. Response to: Status of remdesivir: Not yet beyond question! Arch Med Res. 2021; 52(1): 104-106. doi: 10.1016/j.arc-med.2020.09.005
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vac-cine. JAMA. 2021; 325(8): 780-781. doi: 10.1001/jama.2021.0600
Centers for Disease Control and Prevention (CDC). Prelimi-nary estimates of the prevalence of selected underlying health con-ditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. Web site. https://www.cdc. gov/mmwr/volumes/69/wr/mm6913e2.htm. Accessed April 22, 2020.
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis af-Submit your article to this journal | https://openventio.org/submit-manuscript/ ter receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021; 325(11): 1101-1102. doi: 10.1001/jama.2021.1967
Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recom-binant) use in healthcare workers-first results from India. EClini-calMedicine. 2021; 38: 101038. doi: 10.1016/j.eclinm.2021.101038
Victor PJ, Mathews KP, Paul H, Mammen JJ, Murugesan M. Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India. Mayo Clinic Pro-ceedings. 2021; 96(9): 2493-2494. doi: 10.1016/j.mayocp.2021.06.003
Krishan K, Kanchan T. Lockdown is an effective “vaccine” against COVID-19: A message from India. J Infect Dev Ctries. 2020 Jun 30;14(6):545-546. doi: 10.3855/jidc.12931
Vergara RJD, Sarmiento PJD, Lagman JDN. Building public trust: A response to COVID-19 vaccine hesitancy predicament. Journal of Public Health. 2021; (fdaa282). doi: 10.1093/pubmed/ fdaa282
Mathur M, Mathur N. Vaccine hesitancy among health care workers: A study amidst COVID-19 vaccine drive in India. Int J Epidemiol. 2021; 50(Supplement_1). doi: 10.1093/ije/dyab168.422
Medscape. COVID-19 Treatment: Investigational drugs and other therapies. Web site. Web site. https://emedicine.medscape. com/article/2500116-overview. Accessed March 25, 2021.
Thiagarajan K. COVID-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ. 2021; 372: n196. doi: 10.1136/bmj.n196
Australian Government Department (AGD) of Health. CO-VID-19 vaccination – Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca. Web site. https://www.health.gov.au/resources/publications/covid-19-vac-cination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca. Accessed December 17, 2021.
Centers for Disease Control and Prevention (CDC). Benefits of Getting a COVID-19 Vaccine. Web site. https://www.cdc.gov/ coronavirus/2019-ncov/vaccines/vaccine-benefits.html. Accessed December 17, 2021.
The Conversation. London School of Hygiene & Tropical Medicine. Web site. https://theconversation.com/institutions/ london-school-of-hygiene-and-tropical-medicine-859. Accessed December 4, 2021.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.